OKYO Pharma Ltd (NASDAQ:OKYO)
| Market Cap | $73.47M-41.4% |
| Revenue (ttm) | $0 |
| Net Income | -$8.95M+4.9% |
| EPS | -$0.24-29825.0% |
| Shares Out | 52.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 119,416 |
| Open | $1.37 |
| Previous Close | $1.42 |
| Day's Range | $1.37 - $1.41 |
| 52-Week Range | $1.26 - $3.20 |
| Beta | 0.04 |
| Analysts | Buy |
| Price Target | $5.00(+257.14%) |
| Earnings Date | Dec 2, 2026 |
About OKYO
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Dec 2, 2026Earnings report
$OKYO stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OKYO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OKYO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OKYO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New OKYO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OKYO from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from OKYO’s recent data — informational, not investment advice